@article{25ad5c9c3c4d4c4aa6c30f7c07e6f0f5,
title = "Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling",
author = "Bonow, {Robert O.} and Harrington, {Robert A.} and Yancy, {Clyde W.}",
note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.",
year = "2017",
month = dec,
doi = "10.1001/jamacardio.2017.3656",
language = "English (US)",
volume = "2",
pages = "1298--1299",
journal = "JAMA Cardiology",
issn = "2380-6583",
publisher = "American Medical Association",
number = "12",
}